Dermapharm Holding SE (ETR:DMP)
Germany · Delayed Price · Currency is EUR 43.00
+1.25 (2.99%)
Jul 29, 2026, 4:36 PM CET
Dermapharm Holding SE Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,168 | 1,165 | 1,181 | 1,135 | 1,025 | 942.91 | |
Revenue Growth | -1.36% | -1.34% | 4.00% | 10.79% | 8.68% | 18.78% |
Cost of Revenue | 372.64 | 383.98 | 434.1 | 434.92 | 373.5 | 333.59 |
Gross Profit | 795.75 | 781 | 746.67 | 700.43 | 651.28 | 609.32 |
Selling, General & Admin | 294.95 | 291.57 | 279.8 | 264.48 | 184.14 | 164.66 |
Depreciation & Amortization Expenses | 92.97 | 92.56 | 90.5 | 104.59 | 101.18 | 55.6 |
Other Operating Expenses | 176.29 | 176.2 | 159.44 | 148.47 | 122.27 | 90.59 |
Total Operating Expenses | 564.2 | 560.33 | 529.74 | 517.53 | 407.59 | 310.85 |
Operating Income | 231.55 | 220.67 | 216.93 | 182.89 | 243.69 | 298.47 |
Interest Income | 10.18 | 11.15 | 16.94 | 3.23 | 0.7 | 4.22 |
Interest Expense | -50.47 | -52.66 | -63.39 | -72.96 | -14.54 | -10.04 |
Other Non-Operating Income (Expense) | 4.08 | 4.34 | 1.52 | -7.16 | -13.54 | 0.32 |
Total Non-Operating Income (Expense) | -36.2 | -37.16 | -44.93 | -76.9 | -27.39 | -5.49 |
Pretax Income | 195.35 | 183.51 | 172.01 | 106 | 216.3 | 292.98 |
Provision for Income Taxes | 52.07 | 52.16 | 60.27 | 45.46 | 83.68 | 84.07 |
Net Income | 143.28 | 131.35 | 111.74 | 60.53 | 132.62 | 208.9 |
Minority Interest in Earnings | -0.93 | -1.06 | -2.05 | -1.83 | -1.62 | -0.68 |
Net Income to Common | 144.21 | 132.41 | 113.79 | 62.37 | 134.24 | 209.58 |
Net Income Growth | 39.23% | 16.37% | 82.45% | -53.54% | -35.95% | 144.19% |
Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Outstanding (Diluted) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Change | -0.25% | - | - | - | - | - |
EPS (Basic) | 2.68 | 2.46 | 2.11 | 1.16 | 2.49 | 3.89 |
EPS (Diluted) | 2.68 | 2.46 | 2.11 | 1.16 | 2.49 | 3.89 |
EPS Growth | 39.58% | 16.59% | 81.90% | -53.41% | -35.99% | 144.65% |
Free Cash Flow | 240.85 | 187.03 | 163.14 | 177.88 | 249.52 | 189.17 |
Free Cash Flow Growth | 83.50% | 14.64% | -8.29% | -28.71% | 31.91% | 109.48% |
Free Cash Flow Per Share | 4.48 | 3.47 | 3.03 | 3.30 | 4.63 | 3.51 |
Dividends Per Share | 0.880 | 0.880 | 0.900 | 0.880 | 1.050 | 2.170 |
Dividend Growth | -2.22% | -2.22% | 2.27% | -16.19% | -51.61% | 146.59% |
Gross Margin | 68.11% | 67.04% | 63.24% | 61.69% | 63.55% | 64.62% |
Operating Margin | 19.82% | 18.94% | 18.37% | 16.11% | 23.78% | 31.65% |
Profit Margin | 12.26% | 11.28% | 9.46% | 5.33% | 12.94% | 22.16% |
FCF Margin | 20.61% | 16.05% | 13.82% | 15.67% | 24.35% | 20.06% |
EBITDA | 323.92 | 312.68 | 303.72 | 284.67 | 338.6 | 353.63 |
EBITDA Margin | 27.72% | 26.84% | 25.72% | 25.07% | 33.04% | 37.50% |
EBIT | 231.55 | 220.67 | 216.93 | 182.89 | 243.69 | 298.47 |
EBIT Margin | 19.82% | 18.94% | 18.37% | 16.11% | 23.78% | 31.65% |
Effective Tax Rate | 26.66% | 28.42% | 35.04% | 42.89% | 38.69% | 28.70% |